血管増殖性疾患における細胞循環:潜在的な介入と伝達経路
1Division of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA.
Circulation
|May 23, 2001
まとめ
細胞サイクル阻害は,動脈硬化などの疾患における血管増殖を予防し,逆転させるのに有望であることが示されています. これらの発見を臨床実践に転用するには,標的を絞った投与,適切な細胞標的,および副作用を最小限に抑える必要があります.
科学分野:
- 心血管医学は,心臓血管医学である.
- 細胞生物学 細胞生物学
- 薬理学 薬理学とは
背景:
- 動脈硬化症と回復症は,滑らかな筋肉細胞の増殖によって引き起こされる重要な臨床的課題です.
- 細胞循環の調節は,細胞の成長と血管増殖反応を制御する重要な要因です.
研究 の 目的:
- 細胞サイクルに関する現在の概念と,血管増殖性疾患におけるその役割を見直す.
- これらの状態の治療のための細胞サイクル阻害を含む潜在的な介入について議論する.
- インビトロ細胞サイクル阻害データの臨床応用への翻訳を検証する.
主な方法:
- 細胞循環調節とその標的に関する現在の文献のレビュー.
- 細胞サイクル阻害のための薬物,遺伝,および物理的な方法についての議論.
- 抗増殖剤を含む進行中の臨床試験の分析.
主要な成果:
- 細胞サイクル阻害は,血管増殖を逆転させたり,予防したりする潜在的な戦略です.
- 主な課題は,標的の投与,細胞標的の特定,治療比率の改善などです.
- 増殖抑制療法は,将来の心血管疾患管理に大きな希望をもたらします.
結論:
- 細胞サイクル阻害の効果的な臨床翻訳には,発送,標的化,および安全性への対処が必要です.
- 増殖抑制療法の可能性を活用するために,さらなる研究と臨床試験が不可欠です.
- 細胞周期調節は,血管増殖性疾患の有望な治療法である.
さらに関連する動画
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
10.5K
08:02Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood
Published on: January 6, 2022
1.8K
関連する概念動画
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mechanism of Angiogenesis
6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
